U.S. DoD Said to Allow Use of Apple (AAPL), Samsung Devices (BBRY)
Tweet
Share
E-mail
Get Alerts BBRY Hot Sheet
Join SI Premium – FREE
BlackBerry (Nasdaq: BBRY) and Nokia (NYSE: NOK), along with Microsoft (Nasdaq: MSFT) are on watch today amid news that the U.S. Department of Defense might approve use of Apple (Nasdaq: AAPL) and Samsung mobile devices. The headline crossed at the WSJ, though more color wasn't made immediately available.
The news would be another blow to BlackBerry, which has seen its firm grip on secure government and corporate slip through the cracks. Many enterprises have switched to Google (Nasdaq: GOOG) Android or Apple iOS-equipped handsets, offering employees something of a "bring your own device" scheme.
BlackBerry is moving quick since the debut of its new operating system in January to stem the bleeding. After launching its full-touch Z10 smartphone a few months back, the Waterloo, Ontario-based mobile giant is shipping units of its QWERTY keyboard-equipped Q10 handset this month. Sales have started in the U.K. and several other markets, with Sales in the U.S. and Canada expected to start later in May.
Shares of BlackBerry are off 3.2 percent.
The news would be another blow to BlackBerry, which has seen its firm grip on secure government and corporate slip through the cracks. Many enterprises have switched to Google (Nasdaq: GOOG) Android or Apple iOS-equipped handsets, offering employees something of a "bring your own device" scheme.
BlackBerry is moving quick since the debut of its new operating system in January to stem the bleeding. After launching its full-touch Z10 smartphone a few months back, the Waterloo, Ontario-based mobile giant is shipping units of its QWERTY keyboard-equipped Q10 handset this month. Sales have started in the U.K. and several other markets, with Sales in the U.S. and Canada expected to start later in May.
Shares of BlackBerry are off 3.2 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- This cyber stock is a Top Pick at Jefferies going into Q1 earnings
- Goldman Sachs identifies six call buys to make ahead of earnings
- Sage Therapeutics (SAGE) down 19% as its Parkinson's drug fails Phase 2 trials
Create E-mail Alert Related Categories
Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
